Balanced news tone
News Sentiment
NVCR sentiment intelligence
Novocure Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
65 relevant articles
Price is moving more forcefully than the current news tone suggests.
78/100 classification confidence.
directly relevant articles
high-authority source matches
-5.2% over one week, -8.3% over four weeks, trend active, and near fair-value range.
JPMorgan Initiates Coverage on Novocure (NVCR) with Neutral Outl
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
78/100 classification
One-week reaction
-5.2%
Price reacting lower
Trend fit
Trend active
-8.3% over four weeks
Fair value
-4.0%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
14
Neutral
44
Negative
7
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
TradingView
Direct company coverage
NovoCure Ltd. Actuals & Estimates (LSX:A140ML)
This article provides comprehensive financial data and analyst estimates for NovoCure Ltd. (A140ML) on the Lang & Schwarz Exchange. It covers the company's stock performance, market capitalization, earnings, revenue, and future price forecasts, alongside frequently asked question
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 19:10
- Source
- TradingView
The Motley Fool
Direct company coverage
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 24 Jun 2026 07:00
- Source
- The Motley Fool
The Motley Fool
Direct company coverage
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- The Motley Fool
Seeking Alpha
Direct company coverage
NovoCure: Solid Fundamentals, But TRIDENT Caps Near-Term Upside (NASDAQ:NVCR)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 21 Jun 2026 07:00
- Source
- Seeking Alpha
Market source
Direct company coverage
NovoCure (NVCR) Stock Could Be 45.2% Below Fair Value After TRIDENT Trial Miss
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 20 Jun 2026 07:00
- Source
- Market source
Motley Fool
Direct company coverage
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 19 Jun 2026 17:10
- Source
- Motley Fool
Investor's Business Daily
Direct company coverage
Novocure Tumbles After Cancer-Fighting Medical Device Flops In Brain Cancer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 20:05
- Source
- Investor's Business Daily
Sahm
Direct company coverage
NovoCure (NVCR) Stock Could Be 31.5% Undervalued After TRIDENT Trial Result
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Sahm
Stock Titan
Direct company coverage
Novocure's glioblastoma trial shows survival data, but no primary win
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
GuruFocus
Direct company coverage
Novocure (NVCR) Sees Significant Decline in Stock Price
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- GuruFocus
GuruFocus
Direct company coverage
Novocure (NVCR) Experiences Significant Decline in Stock Price
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- GuruFocus
Stock Titan
Direct company coverage
Novocure (NASDAQ: NVCR) Phase 3 TRIDENT glioblastoma study misses survival endpoint
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
Seeking Alpha
Direct company coverage
Novocure stock falls on late-stage trial setback (NVCR:NASDAQ)
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Seeking Alpha
simplywall.st
Direct company coverage
NovoCure (NVCR) Appoints Frank Leonard To Its Board After Shareholder Vote
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jun 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Frank Leonard’s Board Appointment and Insider Selling Might Change The Case For Investing In NovoCure (NVCR)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Have Insiders Sold NovoCure Shares Recently?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jun 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 May 2026 07:00
- Source
- Market source
StockStory
Industry context
Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 May 2026 07:00
- Source
- StockStory
simplywall.st
Direct company coverage
NovoCure (NVCR) Earnings Story Centers On 20.6% Revenue Growth Versus Ongoing Losses
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 May 2026 07:00
- Source
- simplywall.st
The Motley Fool
Direct company coverage
NovoCure (NVCR) Q1 2026 Earnings Transcript
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Apr 2026 07:00
- Source
- The Motley Fool
Market source
Industry context
Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks’ Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Is NovoCure (NVCR) Now Pricing In Too Much Pessimism After Prolonged Share Price Slump
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 26 Mar 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Mar 2026 07:00
- Source
- Market source
StockStory
Industry context
Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Mar 2026 07:00
- Source
- StockStory
Market source
Industry context
Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 Mar 2026 07:00
- Source
- Market source
Market source
Industry context
Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 10 Mar 2026 07:00
- Source
- Market source
Stock Titan
Direct company coverage
Francis Leonard sells 9,734 NVCR shares, $133K proceeds (NASDAQ: NVCR)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Mar 2026 08:00
- Source
- Stock Titan